Three Motley Fool contributors think they've found relatively safe stocks to buy right now with major market indexes remaining near correction territory. Here's why they like Abbott Laboratories (NYSE ...

Q4 2024 Earnings Call Transcript March 27, 2025 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Intech Investment Management LLC acquired a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and ...

Charles Schwab Investment Management Inc. raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim ...

Harrow, Inc. offers speculative gains from $20s to $30s, with Q4 growth, bullish 2025 revenue guidance, and long-term growth ...

Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 61.33%, which has investors questioning if this is right time to buy.

Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit convinced a federal appeals court Mylan Laboratories Ltd.’s planned ...

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...

On CNBC's “Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous ...

FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 ...